Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Chong

Showing results (121-130 of 122) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 122 results.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
Circulation|July 25, 2022
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Keith A Gillis, Katriona J M Brooksbank, et al.
Pageof 13

Showing results (121-130 of 122) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 122 results.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
Circulation|July 25, 2022
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Keith A Gillis, Katriona J M Brooksbank, et al.
Pageof 13